Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Stocks in this Quantisnow insightHealth Care
Historical context for ELTX
Across the 26 sessions after earlier ELTX headlines, the stock closed higher 13 times and lower 11 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ELTX | SPY |
|---|---|---|---|
| Aug 10, 2026 | Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma | -2.8% | -0.0% |
| Jul 7, 2026 | Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering | -15.0% | -0.5% |
| Jul 2, 2026 | Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | -37.4% | -0.1% |
| Jun 29, 2026 | Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes | +0.0% | +1.6% |
| Jun 18, 2026 | Ladenburg Thalmann resumed coverage on Elicio Therapeutics with a new price target | -18.3% | +0.8% |
| Jun 17, 2026 | Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer | +70.7% | -1.2% |
Quantisnow market dataNASDAQ
ELTX
Elicio Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for ELTX
Full ELTX profile on Quantisnow Follow ELTX and get a push notification the moment its next story breaks.